Nutra Pharma will be conducting a webinar on December 10, 2009, to discuss the Company’s over-the-counter and prescription treatments for chronic pain, Cobroxin and Nyloxin Rx.
Nutra Pharma Corp., a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today that it will be hosting an online webinar on December 10, 2009, at 9PM ET to discuss current progress with Cobroxin and Nyloxin Rx, the Company’s treatments for chronic pain.
“Over the past few months, we have been gaining traction in the pain market through the launch of our over-the-counter pain reliever, Cobroxin, and our recently introduced prescription pain reliever, Nyloxin Rx,” explained Rik J Deitsch, Chairman and CEO of Nutra Pharma Corporation. “We would like to invite all of our shareholders and other interested parties to join us on this webinar so that we may explain our current progress and our short-term and long-term goals,” he added.
Registration is limited. To register for the upcoming webinar, visit http://tinyurl.com/NPHCwebinar.
This press release contains forward-looking statements. The words or phrases "would be," "will allow," "intends to," "will likely result," "are expected to," "will continue," "is anticipated," "estimate," "project," or similar expressions are intended to identify "forward-looking statements." Actual results could differ materially from those projected in Nutra Pharma's ("the Company") business plan. The Company's business is subject to various risks, which are discussed in the Company's filings with the Securities and Exchange Commission ("SEC"). Announcing the upcoming webinar about the Company’s treatments for chronic pain should not be construed as an indication in any way whatsoever of the value of the Company or its common stock. The Company's filings may be accessed at the SEC's Edgar system at www.sec.gov. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date. The Company cautions readers not to place reliance on such statements. Unless otherwise required by applicable law, we do not undertake, and we specifically disclaim any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.